Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2018-2022.

BACKGROUND

Healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) continue to contribute to excess morbidity and mortality among Canadians.

OBJECTIVE

This report describes epidemiologic and laboratory characteristics and trends of HAIs and AMR from 2018 to 2022 (, 2012-2022) using surveillance and laboratory data submitted by hospitals to the Canadian Nosocomial Infection Surveillance Program (CNISP) and by provincial and territorial laboratories to the National Microbiology Laboratory.

METHODS

Data collected from 88 Canadian sentinel acute care hospitals between January 1, 2018, and December 31, 2022, for infections (CDIs), carbapenemase-producing (CPE) infections, methicillin-resistant (MRSA) bloodstream infections (BSIs) and vancomycin-resistant (VRE) BSIs. () surveillance was initiated in 2019 by CNISP and in 2017 (retrospectively to 2012) by the National Microbiology Laboratory. Trend analysis for case counts, rates, outcomes, molecular characterization and AMR profiles are presented.

RESULTS

From 2018 to 2022, decreased rates per 10,000 patient days were observed for CDIs (7% decrease; 5.42-5.02) and MRSA BSIs (2.9% decrease; 1.04-1.01). Infection rates for VRE BSIs increased by 5.9% (0.34-0.36). Infection rates for CPE remained low but increased by 133% (0.06-0.14). Forty-three isolates were identified in Canada from 2012 to 2022, with the majority in Western and Central Canada (98%).

CONCLUSION

From 2018 to 2022, the incidence of MRSA BSIs and CDIs decreased and VRE BSI and CPE infections increased in the Canadian acute care hospitals participating in a national sentinel network (CNISP). Few isolates were identified from 2012 to 2022. Reporting standardized surveillance data to inform the application of infection prevention and control practices in acute care hospitals is critical to help decrease the burden of HAIs and AMR in Canada.